Flu Shots and the mismatch problem: measurable protection, but a season that didn’t line up
Flu shots are showing measurable protection in the 2025-2026 season—even as federal data points to a strain mismatch that helps explain why this year’s performance looks weaker than recent seasons.
What do the latest CDC numbers actually show for Flu Shots?
On March 12 (ET), the U. S. Centers for Disease Control and Prevention released interim findings on influenza vaccine effectiveness for the 2025-2026 season. The estimates show a reduction in risk for people who were vaccinated, but the size of that reduction varies by age group and outcome.
For adults, the CDC estimated the vaccine reduced the risk of medical visits by 22% to 34% and reduced hospitalizations by 30% for all adults. For children and adolescents younger than 18 years, the CDC estimated a 38% to 41% reduction in medical visits and a 41% reduction in hospitalizations.
Additional interim detail from CDC-affiliated analysis led by Patrick Maloney, Ph. D., at the CDC in Atlanta, broke out results by influenza type and setting. Among children and adolescents, effectiveness against influenza A varied from 37% against outpatient visits to 42% against hospitalization across settings. Among adults, estimates ranged from 30% against hospitalization to 34% against outpatient visits across settings. For influenza A(H3N2)-associated outcomes among children and adolescents, vaccine effectiveness was estimated at 35% for outpatient visits and 38% for hospitalizations.
The same CDC-linked analysis reported vaccine effectiveness against influenza B outpatient visits at 63% among adults, and ranging from 45% to 71% among children and adolescents.
If protection exists, why did CDC describe this season as less effective?
The central issue flagged in the CDC material is alignment: the CDC said most flu viruses this season were type A (H3N2) subclade K strains, which were different from the strain chosen for this season’s vaccine. That mismatch is a straightforward, documentable explanation for why the CDC characterized interim effectiveness for the 2025-2026 season as lower than in recent influenza seasons while still showing protection for children, adolescents, and adults.
Those two realities can coexist. A season can be “less effective” compared with prior years and still yield meaningful reductions in medical visits and hospitalizations. The CDC’s interim estimates quantify that tradeoff in practical terms: lower performance relative to other seasons, but not zero protection.
One additional fact shapes the impact of that protection at a population level: as of Feb. 21 (ET), less than half of U. S. adults and children received a flu vaccine for the 2025-2026 season, the CDC said. Lower uptake means the benefits measured in clinical networks do not translate as broadly as they could across communities.
What isn’t being told clearly: the difference between “not perfect” and “no value”
The public argument around seasonal influenza vaccination often collapses into absolutes—either the vaccine “works” or it “fails. ” The CDC’s interim 2025-2026 estimates do not support that binary framing. They show partial protection, with stronger results in children and adolescents than in adults, and variation by influenza type.
Verified fact: the interim numbers show reductions in both outpatient medical visits and hospitalizations, including a 30% reduction in adult hospitalizations and a 41% reduction in hospitalizations among children and adolescents.
Verified fact: the CDC identified a dominant circulating virus category—type A(H3N2) subclade K—that differed from the strain selected for the vaccine, providing a concrete biological mismatch signal during the same season the CDC described as less effective than recent seasons.
Informed analysis (grounded in the CDC figures): when fewer than half of adults and children receive the vaccine, public perceptions of limited effectiveness may be reinforced by visible illness in the community—yet the measurable reductions in medical visits and hospitalizations indicate that, for vaccinated individuals, the intervention retains real-world value even in a mismatch season.
The CDC authors summarized the broader implication in their own terms: “Even in seasons when overall VE is reduced, influenza vaccination has prevented thousands of hospitalizations and deaths. ” That statement does not claim perfect protection; it argues that partial protection can still matter at scale.
For readers looking for a single takeaway: the season’s mismatch helps explain lower-than-recent effectiveness, but flu shots still reduced the likelihood of seeking care and needing hospitalization in the interim CDC estimates—and that distinction is central to an evidence-based public understanding of risk.
